Aegerion Pharmaceuticals

Aegerion appoints Mary Szela CEO

Monday, January 11, 2016

Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela as chief executive officer and a member of Aegerion’s board of directors. Szela brings 27 years of progressive leadership experience to Aegerion as well as valuable expertise building global billion-dollar brands, such as Humira, and advancing pipeline products in the biotechnology and pharmaceutical industries.

[Read More]

Minerva Neurosciences expands executive team

Thursday, March 6, 2014

Minerva Neurosciences, a developer of new therapies to treat neuropsychiatric diseases and disorders, has launched the new company web site ( following the successful transfer of the Minerva Neurosciences corporate headquarters from New Jersey to Cambridge, Mass. The establishment of a new corporate headquarters follows the recent appointment of Rogerio Vivaldi, M.D., MBA, as the new president and CEO, and Marc Beer as the new chairman of the board of directors of Minerva Neurosciences. The company was founded in 2013 by the merger of Cyrenaic Pharmaceuticals and Sonkei Pharmaceuticals.

[Read More]